Finally, several clinical data may be related to the scenario, in particular: 1) the fact that PSP/Reg1A has been suggested as a potential serum marker to detect increased β-cell apoptosis, or its therapeutic response, thus might assist the classification for maturity onset diabetes in the young (MODY) [46]; 2) the presence of REG antibodies in both human and/or rodent type 1 and 2 diabetes, which may represent a maladapted attempt for islet neogenesis [47], [48]. The gene discussed is REG1A; the disease is type 2 diabetes mellitus.